Sorfequiline Drug Asset Due Diligence Report 2026

This Sorfequiline Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Sorfequiline can convert its Small molecule drug profile and mycobacterial ATP synthase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Sorfequiline (query alias: Sorfequiline)
Modality / target	Small molecule drug; mycobacterial ATP synthase; mycobacterial ATP synthase inhibitors
Highest global status	Phase 2
Originator	Eli Lilly & Co., Global Alliance for TB Drug Development
Active developers	Global Alliance for TB Drug Development, Piramal Pharma Limited

The MCP disease footprint includes Pulmonary Tuberculosis, Latent Tuberculosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20262925	Phase 1	Not yet recruiting	20	Primary endpoint not disclosed in English source
NCT07672405	Phase 2	Recruiting	100	Primary endpoint not disclosed in English source
NCT06058299	Phase 2	Active, not recruiting	309	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination With Pretomanid and Linezolid in Adult Participants With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis

Phase 2; n=309; evaluation: Not stated in English source. Reported fields: Proportion of Participants With Stable Sputum Conversion by 8 Weeks,(Mean) = 0.310 % (95%CI, 0.208 - 0.446); Proportion of Participants With Stable Sputum Conversion by 8 Weeks,(Mean) = 0.476 % (95%CI, 0.362 - 0.606)

A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects

Phase 1; n=28; evaluation: Not stated in English source. Reported fields: Area under curve from time 0 hours to last quantifiable concentration (AUC 0-last), with TBAJ-876(Geometric Mean) = 22.64 ng.hr/mL (Full Range, 7.98 - 43.78)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Sorfequiline addresses Pulmonary Tuberculosis, Latent Tuberculosis. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “target-level comparable: mycobacterial ATP synthase.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: mycobacterial ATP synthase records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2018-04-24	Transaction title not available in English source	IND Application	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Discovery of a f-ATP synthase inhibitor for the treatment of non-tuberculous mycobacteria diseases”. The milestone feed surfaced a patent-application signal described as “Antibacterial compounds and uses thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO